Akso Health Gr Stock EBITDA

8HX Stock  EUR 1.20  0.04  3.45%   
Fundamental analysis of AKSO HEALTH allows traders to better anticipate movements in AKSO HEALTH's stock price by examining its financial health and performance throughout various phases of its business cycle.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

AKSO HEALTH GR Company EBITDA Analysis

AKSO HEALTH's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current AKSO HEALTH EBITDA

    
  (15.12 M)  
Most of AKSO HEALTH's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AKSO HEALTH GR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, AKSO HEALTH GR reported earnings before interest,tax, depreciation and amortization of (15.12 Million). This is 100.02% lower than that of the Financial Services sector and 100.73% lower than that of the Credit Services industry. The ebitda for all Germany stocks is 100.39% higher than that of the company.

AKSO EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AKSO HEALTH's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AKSO HEALTH could also be used in its relative valuation, which is a method of valuing AKSO HEALTH by comparing valuation metrics of similar companies.
AKSO HEALTH is currently under evaluation in ebitda category among its peers.

AKSO Fundamentals

About AKSO HEALTH Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze AKSO HEALTH GR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AKSO HEALTH using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AKSO HEALTH GR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in AKSO Stock

AKSO HEALTH financial ratios help investors to determine whether AKSO Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AKSO with respect to the benefits of owning AKSO HEALTH security.